Research programme: small molecule therapeutics - Pfizer/PTC Therapeutics
Latest Information Update: 12 Aug 2009
At a glance
- Originator PTC Therapeutics
- Class Small molecules
- Mechanism of Action Protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 12 Aug 2009 This programme is still in active development
- 11 Jan 2007 Preclinical trials in Undefined in USA (PO)